A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

October 29, 2025

Study Completion Date

October 29, 2025

Conditions
Diabetic Macular EdemaNeovascular Age-related Macular Degeneration
Interventions
DRUG

Aflibercept (BAY86-5321, Eylea)

8 mg, intravitreal injection

Trial Locations (8)

1106

Budapesti Bajcsy-Zsilinszky Korhaz es Rendelointezet, Budapest

1122

Semmelweis Egyetem, Budapest

1133

Budapest Retina Associates, Budapest

4032

Debreceni Egyetem Klinikai Kozpont, Debrecen

10034

Fakultní nemocnice Královské Vinohrady - Urologická klinikay, Prague

150 00

Axon Clinical, s.r.o., Prague

851 07

Univerzitna nemocnica Bratislava, Nem. Sv. Cyrila a Metoda, Bratislava

012 07

Fakultna nemocnica s poliklinikou Zilina, Žilina

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Bayer

INDUSTRY

NCT06591598 - A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter